Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma
Status:
Not yet recruiting
Trial end date:
2025-03-21
Target enrollment:
Participant gender:
Summary
This is a parallel, Phase 2, global, multicenter, randomized, double-blind,
placebo-controlled, dose-ranging, four-arms study for treatment.
The purpose of this study is to assess the efficacy, safety, and tolerability of add-on
therapy with amlitelimab in adult participants with moderate-to-severe asthma.
Study details include:
- The study duration (per participant) will be up to approximately 76 weeks for
participants not going into LTS study and will be up to approximately 64 weeks for
participants going into LTS study.
- The randomized treatment duration will be up to approximately 60 weeks.
- The scheduled number of visits will be 13.